Skip to main content
Premium Trial:

Request an Annual Quote

Agendia Nabs $6.8M Grant for European CRC Subtyping Study

NEW YORK (GenomeWeb) – Dutch molecular diagnostics firm Agendia today announced that it and several partners have received a four-year, $6.8 million grant from the European Commission to study targeted therapies for colorectal cancer.

Along with several European partners, the firm will launch a study to evaluate the effectiveness of matching therapies to molecular subtypes of colorectal cancer. The project is known as "Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer," or MoTriColor. Agendia and its partners will perform Phase II studies across Europe, using Agendia technology to identify tumor subtypes in patients with advanced disease and poor prognosis, the firm said in a statement.

"Our technology has already demonstrated the value of this approach for breast cancer," Rene Bernards, Agendia CSO, said in a statement. Agendia also offers MammaPrint, an FDA-approved technology for subtyping breast cancers from formalin-fixed paraffin-embedded samples.

Agendia said it will work with 10 partner institutions in the Netherlands, Belgium, Spain, and Italy and two undisclosed pharmaceutical companies.

Amsterdam-based Agendia is a spinout from the Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, with US operations in Irvine, California.